Sophia Antipolis, France

MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced that it has been selected to provide imaging services in a new phase II clinical trial. The clinical trial is sponsored by a Top 20 pharmaceutical company and is for a highly aggressive cutaneous cancer type. The anticipated amount for the project is $ 582K equivalent to €422K for MEDIAN.

“This is an important new project awarded through our collaboration with our strategic CRO partner. In parallel, we already have several ongoing clinical studies with this pharmaceutical sponsor. This new study award demonstrates the trust they have in our company” emphasized Nicolas Dano, Director of Business Development, Europe and Asia. “With the award of  this new phase II study for a specific type of cutaneous cancer, we continue to expand the range of cancer indications we cover and for which we provide highly differentiated image management and interpretation services”, he added

Within the framework of the study, imaging data will be acquired from approximately 50 clinical sites worldwide, with a start date forecasted in Q2, 2014.  MEDIAN will provide the whole set of imaging services including Independent Central Review (ICR) services. ICR services will be performed by radiologists using MEDIAN’s Lesion Management Solutions (LMS) software. LMS is a comprehensive suite of software modules for the review of images and quantitative assessment of response to therapy in clinical trials. MEDIAN LMS provide sponsors with very accurate and reliable imaging data.

[*] A project award notifies a company that their solution has been selected for a given project. A binding contract is then signed within the 18 months following the award, upon confirmation of the upstream clinical results.
Download Project_award_april2014.pdf